Dr. Wolf is an Associate Professor in the Departments of Dermatology and Radiation Oncology, as well as a member of the University of Rochester NCI Community Oncology Research Program (NCORP) Research Base and the SWOG Cancer Research Network. Her research and expertise uniquely combines the fields of dermatology, radiation biology, oncology, and health services and outcomes research. Dr. Wolf strives to improve healthcare by facilitating access to evidence-based, integrative, patient-centered care and to optimize metrics for assessing quality of care.
Julie Ryan Wolf, PhD, MPH, is an Associate Professor in the Departments of Dermatology and Radiation Oncology, as well as a member of the University of Rochester NCI Community Oncology Research Program (NCORP) Research Base and the SWOG Cancer Research Network. She received her undergraduate degree from University of Chicago, her PhD in Pathology from UNC-Chapel Hill, and her MPH from University of Rochester. Her research and expertise uniquely combines the fields of dermatology, radiation biology, oncology, and health services and outcomes research. Dr. Wolf strives to improve healthcare by facilitating access to evidence-based, integrative, patient-centered care and to optimize metrics for assessing quality of care. Much of her research has been dedicated to understanding and reducing radiation-induced skin reactions and other cancer-treatment-related toxicities. Her interventions have included non-toxic alternative modalities, such as curcumin, ginger, and aromatherapy. She has performed multiple local and national clinical trials and held two FDA INDs.
Dr. Wolf performs multidisciplinary clinical research that combines dermatology, cancer control, oncology, and health outcomes. She enjoys mentoring and working with medical students, graduate students, and residents. She has conducted multiple local and nationwide clinical trials and has held two FDA INDs (74,555 and 123,414). She received national recognition at ASCO 2009 for the nationwide NCORP trial investigating ginger for chemotherapy-induced nausea. Her NCORP trial investigating oral curcumin for radiation dermatitis in breast cancer patients was the largest botanical product randomized controlled trial to date. A recently completed NCI-supported trial evaluated the effectiveness of prophylactic topical agents for radiation dermatitis and pain. Much of her research has been dedicated to understanding cancer-treatment induced toxicities and evaluating effective interventions to reduce these toxicities. Radiation dermatitis occurs in about 95% of patients and can negatively affect a patient's quality of life due to pain and premature interruption of radiation treatment. Management of radiation dermatitis has a broader significance as well; it has great importance in the morbidity and mortality expected in any potential "dirty bomb" attack. As part of the former University of Rochester Center for Medical Countermeasures Research (CMCR) program grant, Dr. Ryan Wolf investigated the role of altered barrier function and ROS-mediated damage on radiation-induced skin injury and combined radiation skin injury. Dr. Wolf’s research has also focused on elucidating the potential physical and psychosocial factors that influence the frequency and severity of patient-reported outcomes and clinical outcomes, such as skin reactions, pain, anxiety, and itch. Currently, she has a collaborative clinical trial with Roswell Park Cancer Institute, supported by the Wilmot Cancer Institute, investigating the use of aromatherapy as integrative cancer care for chemotherapy-induced symptoms. Another oncology project, in collaboration with Chapman University and SWOG, will evaluate the effectiveness of a novel topical vitamin K1 product for EGFRI-induced rash. Her new dermatology clinical trial, supported by Pfizer, will evaluate the impact of topical tacrolimus and crisaborole treatment on patient-reported outcomes and caregiver burden in children and adolescents with atopic dermatitis. This study will provide valuable insight into how treatment of a chronic disease affects patients, their families, and compliance to therapy. Another project in collaboration with Michigan State University and supported by NSF, involves optimization of a new metric and analysis for quality of care by applying complexity theory to healthcare routines. This novel analysis uses audit trail data from the electronic medical record to evaluate clinic visit process and workflow. Furthermore, Dr. Wolf has established using patient-reported outcome measures (PROMIS domains) as part of routine clinical care in dermatology. Thus far, her work has demonstrated the critical need for patient-reported outcomes in monitoring disease activity and treatment response.
2007 - Present
Investigation New Drug (IND) #75,444 Curcumin C3 Complex, Food & Drug Administration
Sponsor: Center for Drug Evaluation and Res, Div of Drug Oncology Prod
2006 - 2010
National Institutes of Health Clinical Loan Repayment Program
2005 - 2007
National Cancer Institute Cancer Control Research Training Fellowship Award, Dept of Radiation Oncology
Sponsor: James P. Wilmot Cancer Ctr, Univ of Rochester Sch of Med & Dent
2005 - 2007
Rochester Clinical Research Fellow, Dept of Community and Preventative Medicine
Sponsor: University of Rochester School of Med & Dent
Transportation Grant Award, Univ of North Carolina at Chapel Hill Graduate School
Sponsor: 11th Biennial Conf of Internat Assoc Res on Epstein-Barr Virus
Location: Regensberg, Germany
Pathobiology of Cancer: The Edward A. Smuckler Memorial Workshop
Sponsor: American Association of Cancer Research
Location: Snowmass, CO
American Society of Investigative Pathology Travel Award, Experimental Biology Meeting
Location: New Orleans, LA
2001 - 2005
Environmental Pathology Training Grant (#T32 ES07017)
Sponsor: University of North Carolina at Chapel Hill, Dept Path & Lab Med
VIEW ALL expand_more
Esaa F, Prezzano J, Pentland A, Ryan Wolf J. "The utility of PROMIS domain measures in dermatologic care." Archives of dermatological research.. 2020 Apr 8; Epub 2020 Apr 08.
Ryan Wolf J, Gewandter JS, Bautista J, Heckler CE, Strasser J, Dyk P, Anderson T, Gross H, Speer T, Dolohanty L, Bylund K, Pentland AP, Morrow GR. "Utility of topical agents for radiation dermatitis and pain: a randomized clinical trial." Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer.. 2019 Nov 22; Epub 2019 Nov 22.
Peoples AR, Garland SN, Pigeon WR, Perlis ML, Wolf JR, Heffner KL, Mustian KM, Heckler CE, Peppone LJ, Kamen CS, Morrow GR, Roscoe JA. "Cognitive Behavioral Therapy for Insomnia Reduces Depression in Cancer Survivors." Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine.. 2019 Jan 3; Epub 2019 Jan 03.
Books & Chapters
Chapter Title: Radiation Dermatitis
Book Title: Up-To-Date
Author List: Ryan Wolf J, Ling M, Fowler J
Published By: Up-To-Date 2017
Chapter Title: Radiation Dermatitis
Book Title: Up-To-Date
Author List: Ryan JL, Ling M.
Published By: Up-To-Date 2013
Chapter Title: Behavioral Interventions for Side Effects Related to Cancer and Cancer Treatments.
Book Title: Handbook of Behavioral Science and Cancer
Author List: Morrow, GR, Roscoe, JA, Mustian, KM, Hickok, JT, Ryan, JL, Matteson, S
Edited By: S. Miller
Published By: American Psychological Association 2007
VIEW ALL PUBLICATIONS